LGL leukemia is associated with specific immunophenotypic and molecular features, particularly STAT3 and STAT5 mutations and activation of the JAK-STAT3, Fas/Fas-L and NF-κB signaling pathways. This evidence concerns the gene NFKB1 and T-cell large granular lymphocyte leukemia.